About us
Two Paths, One Vision: The Story Behind VILLIGER VALUATION
Two paths crossed over 15 years ago—shaping what is today VILLIGER VALUATION.
One began with a Swiss mathematician, raised in an entrepreneurial family in the city of Roche and Novartis. He grew up watching the drug development industry evolve—shapedd by patent protection, the rise of biotech, and redrawn by the growing divide between innovation and generics. He thrived on modeling—predicting value from minimal data, even at the earliest R&D stages. A mind built for the short game, portfolio management and sharp decisions in environments where information is scarce.
The other began on the Atlantic coast, with a French strategist raised in a medtech entrepreneur family. Her father founded and led an innovative, listed company with European leadership and global reach—eventually acquired by a major U.S. player. Along the way, he lacked the kind of strategic partner he needed. She became what he had searched for but never found—the support that might have spared years of strain, from inception to expansion, through boardrooms, financing, M&A, and public markets. Her edge: advising and modeling based on real-world behavior: the visible moves and the subtle tells. A game-changer in deal-making, critical times and in navigating the long game.
We believed there was something powerful in that combination—cutting through noise to bring clarity.
Life Sciences, and High Growth/High Risk, are our natural playground.
Modeling and valuation are just tools—sharp ones, sure. But for us, the numbers start playing in our minds long before they hit the screen. We sense the chessboard in motion.
And off we go.
We see the world in detail, as structures in motion. We see their patterns.
We distill what matters most in complex environments—layered, subtle, and rarely loud.
Ralph Villiger
EPFL (Lausanne)
University of Oxford
St Petersburg State University
Technical University of Catalonia
Fascinated by the exploration of the unknown, Ralph built a deep foundation in mathematics to decode the algorithms behind business and behavioral patterns. Finance and Life Sciences became his favorite playgrounds—fields where he not only theorized but also pioneered new ways of thinking. He soon became a globally recognized thought leader in Life Sciences valuation.
The building of Bout d’Ouchée Sàrl (aka VILLIGER VALUATION) has been the high point of his mathematical adventure in Life Sciences. There, he brought together all his cumulated experience from stochastic processes to deal terms calibration to advise investment funds, starting with 6th Element Capital LLP, which he co-founded.
A passionate sailor and mountaineer, Ralph’s life was as exploratory as his mind. He inspired many and received the Vasey Vase in 2014 from the Ocean Cruising Club and was named Best Adventurer in 2015 by Outdoor Magazine.
His extraordinary journey was cut short on August 29, 2015, when a rockfall on the Gspaltenhorn—one of his homeland mountains—proved stronger than his risk assessment.
Marie Petit
Sciences Po (Paris)
Université Pierre & Marie Curie (Paris)
National University of Singapore
Rooted in a medtech entrepreneurial family, Marie grew up with an insider’s view of innovation—from first invention to stock market dynamics. Her early exposure to both the strategic and emotional dimensions of building and scaling a healthcare company shaped her sharp instinct for High Growth / High Risk environments. Long before it became her profession, she understood where motivations to act come from—and where misalignments can arise.
She stepped into negotiation early. Before graduating from a double-track in Sciences and Finance & Strategy, she had already closed her first LBO, worked in M&A alongside her studies, pitched her M&A professor a real deal during her master’s, and contributed to several transactions across both low and high-risk sectors. Not long after, she launched her own practice —and later VILLIGER VALUATION.
Marie is also a keen observer of the natural world. A lifelong horsewoman, she loves gardening, producing her own food, and running/biking in the wild.
Where our DNA comes from
The VILLIGER VALUATION team reviews around a hundred R&D projects each year and follows numerous innovative High Growth / High Risk and Life Sciences ventures—both privately held and listed—as well as several investment funds throughout their lifecycle. We have had the privilege of accompanying multiple unicorns from idea to exit, and were early to recognize the potential of breakthrough platforms such as mRNA and ADCs.
Sharing knowledge has always been a core value. Every year, the team leads workshops and mentoring sessions for incubators, innovation-supporting bodies, and companies across all stages of growth.